EpCaM-targeted immunotoxin for advanced cancers

Scientists at Oslo University Hospital have developed an immunotoxin, MOC31PE, comprising a full-length murine antibody against the epithelial surface antigen EpCAM, which is frequently overexpressed in many cancer forms, coupled to Pseudomonas exotoxin A (PE). Under...

HLA-II targeting vaccines

Our team at Oslo University Hospital and University of Oslo has developed a novel targeting sequence that allows for direct targeting of vaccine antigens to immune cells, thereby improving the immunogenicity and efficacy of subunit vaccines. While the technology can...